Stockreport

Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions

AKCEA THERAPEUTICS  (AKCA) 
Last akcea therapeutics earnings: 2/25 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.akceatx.com/media-investors/press-releases
PDF Approximately 98% of patients receiving highest dose achieved reductions in Lp(a) levels below the established threshold of risk for CVD events [Read more]